Piper Sandler Reiterates Buy Rating on Moderna, Inc.
Piper Sandler maintains its buy rating for Moderna with a target price of $77, a 9.95% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on Moderna, Inc. (MRNA) with a price target of $77, according to analyst Edward Tenthoff on June 26, 2026.
- Piper Sandler's $77 price target implies 9.95% upside from Moderna, Inc.'s ($MRNA) current $70.03 share price.
- Shares of Moderna traded near $59.75 on Friday with a market cap of about $23.7 billion and a 52-week range between $22.28 and $67.74.
- Insiders at Moderna, including President Stephen Hoge, have been active with recent buys and sells, while analysts have a mixed outlook with a consensus hold rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler has reiterated its buy rating on Moderna, Inc. (NasdaqGS: MRNA) with a price target of $77. Analyst Edward Tenthoff confirmed the rating on June 26, 2026. This comes as Moderna's shares traded around $59.75 on Friday.
Piper Sandler vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Moderna
FMR LLC significantly increased its stake in Moderna, adding 17.6 million shares to hold a total of 45.7 million shares valued at approximately $2.32 billion, marking a 62.9% increase. BlackRock, Inc. trimmed its position by 2.87 million shares, ending with 29.6 million shares worth $1.51 billion, an 8.8% decrease. Vanguard Capital Management LLC opened a new position with 22.9 million shares valued at $1.16 billion. Baillie Gifford & Co reduced its holdings by 594,638 shares, now holding about 20 million shares valued at $1.02 billion, a 2.9% decrease. Capital World Investors increased its stake by 5.87 million shares to a total of 18.7 million shares worth $949.8 million, a 45.8% increase.
Moderna, Inc. Stock Down 49.2%
Shares of Moderna traded near $59.75 on Friday. The company has a market cap of approximately $23.7 billion and a forward P/E that is not meaningful due to its lack of profitability. Moderna's beta is 1.03, indicating slightly more volatility than the market. The stock has seen a 52-week low of $22.28 and a high of $67.74. Its 50-day moving average is $50.90, and the 200-day moving average is $39.93. The company maintains a solid liquidity position with a current ratio of 2.41 and a quick ratio of 2.24, alongside a debt-to-equity ratio of 17.52.
$MRNA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Moderna reported revenue of $2.22 billion, reflecting a modest growth rate of 2.6%. However, the company is currently not profitable, with a net margin of -143.6% and a return on equity of -36.6%. The next earnings announcement is scheduled for May 1, 2026.
Insider Buying and Selling at Moderna, Inc.
On June 15, 2026, President Stephen Hoge made several transactions, including a purchase of 53,336 shares at $19.15 and a planned sale of the same amount at $51.37. Additionally, on June 5, 2026, Chief Legal Officer Shannon Thyme Klinger and Chief Financial Officer James Mock each bought 11,798 shares.
Analysts Set New Price Targets
On June 26, 2026, Piper Sandler maintained its buy rating on Moderna with a price target of $77. B of A Securities kept its sell rating with a target of $34 on June 8, 2026. UBS, Goldman Sachs, Evercore ISI Group, and RBC Capital all maintained hold ratings with targets ranging from $38 to $50 in early May 2026. The consensus among analysts is a hold rating, with an average target price of $43.45 based on 20 analyst opinions.
About Moderna, Inc.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts. Founded in 2010, it specializes in messenger RNA medicines, developing vaccines for a range of viruses including COVID-19, RSV, and influenza. The company also works on oncology therapeutics and treatments for rare diseases. Moderna collaborates with several partners, including Merck & Co., Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. It is led by CEO Stéphane Bancel and employs about 4,700 people.
Bottom Line
Piper Sandler's reiteration of a buy rating with a $77 target reflects confidence in Moderna's prospects, despite current financial challenges. Investors and analysts continue to watch Moderna closely, especially given the company's innovative approach to vaccines and therapeutics. As with all 13F filings and analyst updates, these ratings and holdings reflect past data and may not indicate current positions.
Get Moderna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MRNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.